Albiges L - Search Results

1

Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.

Rassy E, Dalban C, Colomba E, Derosa L, Alves Costa Silva C, Negrier S, Chevreau C, Gravis G, Oudard S, Laguerre B, Barthelemy P, Goupil MG, Geoffrois L, Rolland F, Thiery-Vuillemin A, Joly F, Ladoire S, Tantot F, Escudier B, Albiges L. Rassy E, et al. Among authors: albiges l. Clin Genitourin Cancer. 2022 Oct;20(5):488-494. doi: 10.1016/j.clgc.2022.07.003. Epub 2022 Jul 10. Clin Genitourin Cancer. 2022. PMID: 35977881 Clinical Trial.

2

[New drugs in metastatic castration-resistant prostate cancer].

Albiges L, Loriot Y, Gross-Goupil M, de La Motte Rouge T, Blesius A, Escudier B, Massard C, Fizazi K. Albiges L, et al. Bull Cancer. 2010 Jan;97(1):149-59. doi: 10.1684/bdc.2009.1023. Bull Cancer. 2010. PMID: 20022854 Free article. French.

3

Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography.

Lassau N, Koscielny S, Albiges L, Chami L, Benatsou B, Chebil M, Roche A, Escudier BJ. Lassau N, et al. Among authors: albiges l. Clin Cancer Res. 2010 Feb 15;16(4):1216-25. doi: 10.1158/1078-0432.CCR-09-2175. Epub 2010 Feb 9. Clin Cancer Res. 2010. PMID: 20145174

4

How to select targeted therapy in renal cell cancer.

Escudier B, Albiges L, Blesius A, Loriot Y, Massard C, Fizazi K. Escudier B, et al. Among authors: albiges l. Ann Oncol. 2010 Oct;21 Suppl 7:vii59-62. doi: 10.1093/annonc/mdq371. Ann Oncol. 2010. PMID: 20943644 Free article. Review.

5

Vascular endothelial growth factor-targeted therapy for the treatment of renal cell carcinoma.

Escudier B, Albiges L. Escudier B, et al. Among authors: albiges l. Drugs. 2011 Jun 18;71(9):1179-91. doi: 10.2165/11591410-000000000-00000. Drugs. 2011. PMID: 21711062 Review.

6

Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.

Albiges L, Salem M, Rini B, Escudier B. Albiges L, et al. Hematol Oncol Clin North Am. 2011 Aug;25(4):813-33. doi: 10.1016/j.hoc.2011.04.006. Hematol Oncol Clin North Am. 2011. PMID: 21763969 Review.

7

Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: feasibility and clinical outcome.

Sadeghi S, Albiges L, Wood LS, Black SL, Gilligan TD, Dreicer R, Garcia JA, Escudier BJ, Rini BI. Sadeghi S, et al. Among authors: albiges l. Cancer. 2012 Jul 1;118(13):3277-82. doi: 10.1002/cncr.26666. Epub 2011 Dec 2. Cancer. 2012. PMID: 22139966 Free article.

8

Complete remission with tyrosine kinase inhibitors in renal cell carcinoma.

Albiges L, Oudard S, Negrier S, Caty A, Gravis G, Joly F, Duclos B, Geoffrois L, Rolland F, Guillot A, Laguerre B, Legouffe E, Kohser F, Dietrich PY, Theodore CA, Escudier B. Albiges L, et al. J Clin Oncol. 2012 Feb 10;30(5):482-7. doi: 10.1200/JCO.2011.37.2516. Epub 2012 Jan 9. J Clin Oncol. 2012. PMID: 22231040

9

Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum-gemcitabine regimen.

Edeline J, Loriot Y, Culine S, Massard C, Albiges L, Blesius A, Escudier B, Fizazi K. Edeline J, et al. Among authors: albiges l. Eur J Cancer. 2012 May;48(8):1141-6. doi: 10.1016/j.ejca.2012.01.022. Epub 2012 Feb 22. Eur J Cancer. 2012. PMID: 22364733

10

Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma.

Albiges L, Chamming's F, Duclos B, Stern M, Motzer RJ, Ravaud A, Camus P. Albiges L, et al. Ann Oncol. 2012 Aug;23(8):1943-1953. doi: 10.1093/annonc/mds115. Epub 2012 Jun 11. Ann Oncol. 2012. PMID: 22689175 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

312 results

Search Page